Recommendation
==============

Guideline
---------

S3-Leitlinie Empfehlungen zur stationären Therapie von Patienten mit COVID-19 – Living Guideline - <https://register.awmf.org/de/leitlinien/detail/113-001LG>

Summary
-------

### German

Hospitalisierte Patienten mit COVID-19 sollen in Abwesenheit von Kontraindikationen eine standardmäßige medikamentöse Thromboembolieprophylaxe mit niedermolekularem Heparin erhalten. Alternativ kann Fondaparinux zur Anwendung kommen. ⇑⇑

### English (machine translation)

Hospitalized patients with COVID-19 should receive standard drug thromboembolism prophylaxis with low molecular weight heparin in the absence of contraindications. Alternatively, fondaparinux may be used. ⇑⇑

Justification
-------------

### German

Thromboembolische Ereignisse sind eine häufige Komplikation bei COVID-19 und betreffen vorwiegend das venöse, jedoch auch das arterielle Gefäßsystem (112-114). Alle stationär behandelten Patienten sollen daher zur Prophylaxe einer venösen Thromboembolie (VTE) niedermolekulares Heparin (NMH) in einer für den Hochrisikobereich zugelassenen Dosierung erhalten, z. B. Enoxaparin 4.000 IE, Dalteparin 5.000 IE, Tinzaparin 4.500 IE, Certoparin 3.000 IE, Nadroparin (< 70kg KG 3.800 IE, > 70kg KG 5.700 IE). Alternativ, z.B. bei Heparinunverträglichkeit oder stattgehabter heparininduzierter Thrombozytopenie (HIT), ist die Gabe von Fondaparinux möglich. Die Empfehlung basiert auf der S3-Leitlinie Prophylaxe der venösen Thromboembolie (115). Der Nutzen einer medikamentösen VTE-Prophylaxe, vorzugsweise mit NMH, bei stationären Patienten mit akuten internistischen Erkrankungen und Bettlägerigkeit wurde in mehreren randomisierten Studien prospektiv untersucht. Bezüglich hospitalisierter Patienten mit COVID-19 liegen zwar keine spezifischen Studiendaten zur VTE-Prophylaxe vor; die bisher verfügbare Evidenz ist aber auf die Pandemiesituation übertragbar. Unter Berücksichtigung von Kontraindikationen reduziert die Thromboseprophylaxe mit NMH (oder alternativ mit Fondaparinux) hochwirksam das VTE-Risiko, ohne das Risiko für schwere Blutungen signifikant zu erhöhen.

### English (machine translation)

Thromboembolic events are a common complication of COVID-19 and predominantly affect the venous but also the arterial vasculature (112-114). Therefore, all hospitalized patients should receive low-molecular-weight heparin (NMH) for prophylaxis of venous thromboembolism (VTE) at a dosage approved for high-risk settings, e.g., enoxaparin 4,000 IU, dalteparin 5,000 IU, tinzaparin 4,500 IU, certoparin 3,000 IU, nadroparin (< 70kg bw 3,800 IU, > 70kg bw 5,700 IU). Alternatively, e.g. in cases of heparin intolerance or previous heparin-induced thrombocytopenia (HIT)  
administration of fondaparinux is possible. The recommendation is based on the S3 guideline Prophylaxis of venous thromboembolism (115). The benefit of drug-based VTE prophylaxis, preferably with NMH, in hospitalized patients with acute internal diseases and bed confinement, has been prospectively investigated in several randomized trials. Regarding hospitalized patients with COVID-19, there are no specific trial data on VTE prophylaxis; however, the evidence available to date is applicable to the pandemic situation. Considering contraindications, thromboprophylaxis with NMH (or alternatively with fondaparinux) is highly effective in reducing the risk of VTE without significantly increasing the risk of major bleeding.

Population
==========



| Name | Description | Criteria |
| --- | --- | --- |
|  |  | Inclusion  /Exclusion  | Name | Category | definition.type | definition.value |
| PopHospitalisedCOVID19PatientsWOContraIndications | Population for recommendation 15: Hospitalised COVID-19 patients without contraindications to LWMH. |  | COVID-19 | Condition | SCT [404684003 "Clinical finding (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=404684003&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#840539006 "Disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder)" |
| *any-of* | HIT 2 | Condition | SCT [404684003 "Clinical finding (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=404684003&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#111588002 "Heparin-induced thrombocytopenia with thrombosis (disorder)" |
| Heparin Allergy | Allergy | SCT [609328004 "Allergic disposition (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=609328004&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#294872001 "Allergy to heparin (finding)" |
| Heparinoid Allergy | Allergy | SCT [609328004 "Allergic disposition (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=609328004&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#294876003 "Allergy to heparinoid (finding)" |
| PopHospitalisedCOVID19PatientsWithContraIndications | Population for recommendation 15: Hospitalised COVID-19 patients with existing contraindications to LWMH. |  | COVID-19 | Condition | SCT [404684003 "Clinical finding (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=404684003&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#840539006 "Disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder)" |
| *any-of* | HIT 2 | Condition | SCT [404684003 "Clinical finding (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=404684003&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#111588002 "Heparin-induced thrombocytopenia with thrombosis (disorder)" |
| Heparin Allergy | Allergy | SCT [609328004 "Allergic disposition (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=609328004&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#294872001 "Allergy to heparin (finding)" |
| Heparinoid Allergy | Allergy | SCT [609328004 "Allergic disposition (finding)](https://browser.ihtsdotools.org/?perspective=full&conceptId1=609328004&edition=MAIN/2022-04-30&release=&languages=en)" | $sct#294876003 "Allergy to heparinoid (finding)" |

Intervention
============

| Name | Description | Population | Actions/Activities |
| --- | --- | --- | --- |
|  |  |  | Name | Action Category | productCodeableConcept | Drug Dosage | doNotPerform |
| AntithrombLWMHProphInHospitalisedCOVID19PatientsRecommPlan | Antithrombotic prophylaxis with LWMH in hospitalised COVID-19 patients | PopHospitalisedCOVID19PatientsWithContraIndications | ProphylacticAnticoagulationWDalteparin | drugAdministration | $atcde#B01AB04 "Dalteparin" $sct#372563008 "Dalteparin (substance)" | = 5000 IU/d |  |
| ProphylacticAnticoagulationWEnoxaparin | drugAdministration | $atcde#B01AB05 "Enoxaparin" $sct#372562003 "Enoxaparin (substance)" | = 40 mg/d |  |
| ProphylacticAnticoagulationWNadroparinLowWeight | drugAdministration | $atcde#B01AB06 "Nadroparin" $sct#699946002 "Nadroparin (substance)" | = 3800 IE/d |  |
| ProphylacticAnticoagulationWNadroparinHighWeight | drugAdministration | $atcde#B01AB06 "Nadroparin" $sct#699946002 "Nadroparin (substance)" | = 5700 IE/d |  |
| ProphylacticAnticoagulationWCertoparin | drugAdministration | $atcde#B01AB13  "Certoparin" $sct#395961003 "Certoparin (substance)" | = 3000 IE/d |  |
| ProphylacticAnticoagulationWTinzaparin | drugAdministration | $atcde#B01AB10 "Tinzaparin" $sct#412608008 "Tinzaparin (substance)" | = 4500 IE/d |  |
| AntithrombFondapProphInHospitalisedCOVID19PatientsRecommPlan | Antithrombotic prophylaxis with Fondaparinux in hospitalized COVID-19 patients | PopHospitalisedCOVID19PatientsWOContraIndications | AntithromboticProphylaxisFondaparinuxSubcutaneous | drugAdministration | $atcde#B01AX05 "Fondaparinux" $sct#708189008 "Fondaparinux (substance)" | = 2.5 'mg'/day |  |
 
